12221 related articles for article (PubMed ID: 33377359)
1. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
4. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Bui NN; Lin YT; Huang SH; Lin CW
Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
[TBL] [Abstract][Full Text] [Related]
5. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
6. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
7. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
Manali M; Bissett LA; Amat JAR; Logan N; Scott S; Hughes EC; Harvey WT; Orton R; Thomson EC; Gunson RN; Viana M; Willett B; Murcia PR
J Infect Dis; 2022 Dec; 227(1):40-49. PubMed ID: 35920058
[TBL] [Abstract][Full Text] [Related]
9. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
[TBL] [Abstract][Full Text] [Related]
10. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
11. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
Peters MH; Bastidas O; Kokron DS; Henze CE
Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
[TBL] [Abstract][Full Text] [Related]
12. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
Front Immunol; 2021; 12():730766. PubMed ID: 34630410
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies mediate virus-immune pathology of COVID-19.
Jacobs JJL
Med Hypotheses; 2020 Oct; 143():109884. PubMed ID: 32512289
[TBL] [Abstract][Full Text] [Related]
14. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapy in COVID-19.
Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
[TBL] [Abstract][Full Text] [Related]
16. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
[TBL] [Abstract][Full Text] [Related]
17. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
[TBL] [Abstract][Full Text] [Related]
18. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
Jia Z; Gong W
J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
